Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 4th Edition

09 Dec 2010 • by Natalie Aster

New York – “Drug discovery is a high-cost, risky business because only a fraction of the therapeutic targets selected for study will actually yield products that achieve regulatory approval by the Food & Drug Administration (FDA). The average drug can take 10+ years to progress from the discovery phase to the clinic, with only one compound out of 10,000 evolving into a viable product.”

Through outsourcing portions of their drug discovery programs, many pharmaceutical and biotechnology companies have found an effective cost-cutting strategy that can also improve the hit-to-lead conversion and early identification of unsuccessful compounds. In view of the fact that outsourcing can accelerate the drug discovery process, the business of contract drug discovery has evolved from providing low-end research services to more value-added high-end research.

The report “Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 4th Edition ” by Kalorama Information presents viewpoints from both customers and suppliers, and provides market size, and growth forecasts broken out by segment. The trend towards the increased use of offshore suppliers is covered in detail. The report also provides profiles of 22 suppliers active in this market.

Report Details:

Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 4th Edition

Date: June 2010
Pages: 160
Price: US$ 3,995.00

Report Sample Abstract:

Most of the arguments for drug discovery outsourcing have focused on the cost-saving benefits. However, today companies are outsourcing to gain strategic benefits such as access to innovative technology, faster response time to support and benchmark internal programs, and on-going process improvements. It is not only large pharmaceutical and biopharmaceutical companies that are moving their outsourcing offshore, but smaller biopharmaceutical companies are following this trend as well.

Segments covered in the report include:

  • Chemistry Services (Building Blocks, Compound Synthesis, Libraries, Process Research, Other Services);
  • Biology Services (Protein Expression, Structural Analysis, Target Validation, Pathways Analysis, Other Services);
  • Screening Services (Assay Development, Primary Screening, Secondary Screening);
  • Lead Optimization (Early ADMET, Analogues Creation, Computational Support, Other services).

The report looks offshore at outsourcing suppliers based in three major areas: India, China, and Eastern Europe. The relative advantages each country provides are contrasted with some of their limitations. The report assesses which projects are moving to which suppliers and why.

More information can be found in the report “Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 4th Edition ” by Kalorama Information .

To order the report or ask for sample pages contact ps@marketpublishers.com

Contacts

MarketPublishers, Ltd.
Mrs. Alla Martin
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
www.marketpublishers.com